Cardiovascular, Renal and Metabolism

Visit MyAstraZeneca for more information on our therapeutic areas.

The cardiovascular, renal, and metabolic systems are deeply interconnected. Conditions such as heart failure, chronic kidney disease (CKD), and metabolic disorders like type 2 diabetes share common risk factors and biological drivers. Through dedicated clinical research into these connections, AstraZeneca Switzerland aims to diagnose patients earlier, implement targeted interventions, and halt disease progression.

Our focus areas

Cardiovascular

We aim to prevent severe cardiovascular events by protecting blood vessels and heart function. Through early detection and targeted therapies, we aim to reduce risks and improve long-term heart health for patients across Switzerland.

Heart failure

Effective heart failure management relies on timely, early intervention.1 We are committed to advancing treatments that protect heart function, decrease the need for hospital admissions, and support patients in living active, fulfilling lives.

Renal

Chronic kidney disease (CKD) frequently develops silently2 and is closely linked to heart and metabolic conditions.3 We prioritise early diagnostic strategies and organ-protective therapies designed to slow disease progression and prevent irreversible kidney damage.

Metabolism

Metabolic disorders including type 2 diabetes, have a profound impact on overall health and organ function.4 Our research focuses on innovative treatments that target underlying metabolic drivers, aiming to protect vital organs and enhance long-term patient outcomes.

For more information on AstraZeneca’s therapeutic areas - including disease risks, symptoms, early diagnosis and treatment options - visit myastrazeneca.ch

Learn more here

References

  1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599-3726. Available at: https://doi.org/10.1093/eurheartj/ehab368 (accessed September 2026).
  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S117-S314. Available at: KDIGO Clinical Practice Guideline (accessed September 2026).
  3. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143(11):1157-1172. Available at: https://doi.org/10.1161/CIRCULATIONAHA.120.050686 (accessed September 2026).
  4. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018;14(2):88-98. Available at: https://doi.org/10.1038/nrendo.2017.151 (accessed September 2026).

Veeva ID: CH-13771
Date of preparation: October 2026